Four-year clinical update from a prospective trial of accelerated partial breast intensity-modulated radiotherapy (APBIMRT)

Rachel Y Lei, Charles E Leonard, Kathryn T Howell, Phyllis L Henkenberns, Timothy K Johnson, Tracy L Hobart, Shannon P Fryman, Jane M Kercher, Jodi L Widner, Terese Kaske, Dennis L Carter, Rachel Y Lei, Charles E Leonard, Kathryn T Howell, Phyllis L Henkenberns, Timothy K Johnson, Tracy L Hobart, Shannon P Fryman, Jane M Kercher, Jodi L Widner, Terese Kaske, Dennis L Carter

Abstract

This prospective Phase II single-arm study gathered data on the use of intensity-modulated radiotherapy (IMRT) to deliver accelerated partial breast irradiation (APBI). Four-year efficacy, cosmesis, and toxicity results are presented. Between February 2004 and September 2007, 136 consecutive patients with Stage 0/I breast cancer and negative margins ≥0.2 cm were treated on protocol. Patients received 38.5 Gy in 10 equal fractions delivered twice daily. Breast pain and cosmesis were rated by patient, and cosmesis was additionally evaluated by physician per Radiation Therapy Oncology Group (RTOG) criteria. The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v3.0) was used to grade toxicities. 136 patients (140 breasts) with median follow-up of 53.1 months (range, 8.9-83.2) were evaluated. Population characteristics included median age of 61.9 years and Tis (13.6 %), T1a (18.6 %), T1b (36.4 %), and T1c (31.4 %). Kaplan-Meier estimates at 4 years: ipsilateral breast tumor recurrence 0.7 %; contralateral breast failure 0 %; distant failure 0.9 %; overall survival 96.8 %; and cancer-specific survival 100 %. At last follow-up, patients and physicians rated cosmesis as excellent/good in 88.2 and 90.5 %, respectively; patients rated breast pain as none/mild in 97.0 %. Other observations included edema (1.4 %), telangiectasia (3.6 %), five cases of grade 1 radiation recall (3.6 %), and two cases of rib fractures (1.4 %). This analysis represents the largest cohort and longest follow-up of APBI utilizing IMRT reported to date. Four-year results continue to demonstrate excellent local control, survival, cosmetic results, and toxicity profile.

Trial registration: ClinicalTrials.gov NCT01185145.

Figures

Fig. 1
Fig. 1
Cosmesis and pain outcomes, legend: cosmesis: marbled gray poor, striped gray fair, solid light gray good, solid dark gray excellent, pain: striped gray moderate, solid light gray mild, solid dark gray none, excellent/good cosmesis: dotted line withdiamond markers patient-rated, solid linewith squaremarkers physician-rated

References

    1. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aquilar M, Marubini E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–1232. doi: 10.1056/NEJMoa020989.
    1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med. 2002;347:1233–1241. doi: 10.1056/NEJMoa022152.
    1. EORTC Breast Cancer Cooperative Group. EORTC Radiotherapy Group. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–3387. doi: 10.1200/JCO.2006.06.1366.
    1. Solin LJ, Fourquet A, Vicini FA, Taylor M, Olivotto IA, Haffty B, Strom EA, Pierce LJ, Marks LB, Bartelink H, McNeese MD, Jhingran A, Wai E, Bihjker N, Campana F, Hwang WT. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103:1137–1146. doi: 10.1002/cncr.20886.
    1. Gilligan MA, Kneusel RT, Hoffmann RG, Greer AL, Nattinger AB. Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption. Med Care. 2002;40:181–189. doi: 10.1097/00005650-200203000-00002.
    1. Nattinger AB, Kneusel RT, Hoffmann RG, Gilligan MA. Relationship of distance from a radiotherapy facility and initial breast cancer treatment. J Natl Cancer Inst. 2001;93:1344–1346. doi: 10.1093/jnci/93.17.1344.
    1. Nattinger AB, Hoffmann RG, Kneusel RT, Schapira MM. Relation between appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast-conserving surgery. Lancet. 2000;356:1148–1153. doi: 10.1016/S0140-6736(00)02757-4.
    1. Offersen BV, Overgaard M, Kroman N, Overgaard J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol. 2009;90:1–13. doi: 10.1016/j.radonc.2008.08.005.
    1. NSABP B-39/RTOG 0413 protocol. . Accessed 9 Jan 2013
    1. Polgár C, Fodor J, Major T, Németh G, Lövey K, Orosz Z, Sulyok Z, Takácsi-Nagy Z, Kásler M. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma: 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702. doi: 10.1016/j.ijrobp.2007.04.022.
    1. Hattangadi JA, Powell SN, MacDonald SM, Mauceri T, Ancukiewicz M, Freer P, Lawenda B, Alm El-Din MA, Gadd MA, Smith BL, Taghian AG. Accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial. Int J Radiat Oncol Biol Phys. 2012;83:791–800. doi: 10.1016/j.ijrobp.2011.09.003.
    1. Polgár C, Major T, Fodor J, Sulyok Z, Somogyi A, Lövey K, Németh G, Kásler M. Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol. 2010;94:274–279. doi: 10.1016/j.radonc.2010.01.019.
    1. Shah C, Antonucci JV, Wilkinson JB, Wallace M, Ghilezan M, Chen P, Lewis K, Mitchell C, Vicini F. Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol. 2011;100:210–214. doi: 10.1016/j.radonc.2011.03.011.
    1. Vicini FA, Antonucci JV, Wallace M, Gilbert S, Goldstein NS, Kestin L, Chen P, Kunzman J, Boike T, Benitez P, Martinez A. Long-term efficacy and patterns of failure after accelerated partial breast irradiation: a molecular assay-based clonality evaluation. Int J Radiat Oncol Biol Phys. 2007;68:341–346. doi: 10.1016/j.ijrobp.2006.12.007.
    1. Chen PY, Vicini FA, Benitez P, Kestin LL, Wallace M, Mitchell C, Pettinga J, Martinez AA. Long-term cosmetic results and toxicity after accelerated partial-breast irradiation: a method of radiation delivery by interstitial brachytherapy for the treatment of early-stage breast carcinoma. Cancer. 2006;106:991–999. doi: 10.1002/cncr.21681.
    1. Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker A, White J, Hedberg P, Hebert M, Arthur D, Zannis V, Quiet C, Streeter O, Silverstein M. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg. 2007;194:456–462. doi: 10.1016/j.amjsurg.2007.06.010.
    1. Beitsch PD, Wilkinson JB, Vicini FA, Haffty B, Fine R, Whitworth P, Kuerer H, Zannis V, Lyden M. Tumor bed control with balloon-based accelerated partial breast irradiation: incidence of true recurrences versus elsewhere failures in the American Society of Breast Surgery MammoSite Registry Trial. Ann Surg Oncol. 2012;19:3165–3170. doi: 10.1245/s10434-012-2489-x.
    1. Khan AJ, Arthur D, Vicini F, Beitsch P, Kuerer H, Goyal S, Lyden M, Haffty BG. Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy registry trial. Ann Surg Oncol. 2012;19:1477–1483. doi: 10.1245/s10434-011-2133-1.
    1. Vicini FA, Keisch M, Shah C, Goyal S, Khan AJ, Beitsch PD, Lyden M, Haffty BG. Factors associated with optimal long-term cosmetic results in patients treated with accelerated partial breast irradiation using balloon-based brachytherapy. Int J Radiat Oncol Biol Phys. 2012;83:512–518.
    1. Chao KK, Vicini FA, Wallace M, Mitchell C, Chen P, Ghilezan M, Gilbert S, Kunzman J, Benitez P, Martinez A. Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: The William Beaumont Hospital experience. Int J Radiat Oncol Biol Phys. 2007;69:32–40. doi: 10.1016/j.ijrobp.2007.02.026.
    1. Pashtan IM, Recht A, Ancukiewicz M, Brachtel E, Abi-Raad RF, D’Alessandro HA, Levy A, Wo JY, Hirsch AE, Kachnic LA, Goldberg S, Specht M, Gadd M, Smith BL, Powell SN, Taghian AG. External beam accelerated partial-breast irradiation using 32 Gy in 8 twice-daily fractions: 5 year results of a prospective study. Int J Radiat Oncol Phys. 2012;84:e271–e277. doi: 10.1016/j.ijrobp.2012.04.019.
    1. Taghian AG, Alm El-Din M, Smith BL, Ancukiewicz M, MacDonald SS, Katz A, Specht M, Hirsch A, Powell SN, Recht A. Interim results of a phase I/II trial of 3D-conformal external beam accelerated partial breast irradiation in patients with early breast cancer [Abstract]. Presented at the American Society for Radiation Oncology 50th Annual Meeting, September 21–25, Boston. MA. Int J Radiat Oncol Phys. 2008;72(Suppl):S4. doi: 10.1016/j.ijrobp.2008.06.776.
    1. Formenti SC, Hsu H, Fenton-Kerimian M, Roses D, Guth A, Jozsef G, Goldberg JD, Dewyngaert JK. Prone accelerated partial breast irradiation after breast-conserving surgery: five-year results of 100 patients. Int J Radiat Oncol Biol Phys. 2012;84:606–611. doi: 10.1016/j.ijrobp.2012.01.039.
    1. Vicini F, Winter K, Wong J, Pass H, Rabinovitch R, Chafe S, Arthur D, Petersen I, White J, McCormick B. Initial efficacy results of RTOG 0319: Three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010;77:1120–1127. doi: 10.1016/j.ijrobp.2009.06.067.
    1. Shah C, Wilkinson JB, Lanni T, Jawad M, Wobb J, Fowler A, Wallace M, Chen P, Grillis IS, Vincini F. Five-year outcome and toxicities using 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Clin Breast Cancer. 2012;12:259–263. doi: 10.1016/j.clbc.2012.04.006.
    1. Chen PY, Wallace M, Mitchell C, Grillis I, Kestin L, Fowler A, Martinez A, Vicini F. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:991–997. doi: 10.1016/j.ijrobp.2009.03.012.
    1. Julian TB, Constantino JP, Vicini FA, White JR, Winter A, Arthur DW, Kuske RR, Rabinovitch R, Curran WJ, Jr, Wolmark N. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial [Abstract]. Presented at the American Society for Radiation Oncology 53rd Annual Meeting, October 2–6, Miami Beach, FL. Int J Radiat Oncol Phys. 2011;81(Suppl):S7.
    1. Berrang TS, Olivotto I, Kim DH, Nichol A, Cho BC, Mohamed IG, Parhar T, Wright JR, Truong P, Tyldesley S, Sussman J, Wai E, Whelan T. Three-year outcomes of a Canadian multicenter study of accelerated partial breast irradiation using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2011;81:1220–1227. doi: 10.1016/j.ijrobp.2010.07.2003.
    1. Whelan TJ, Olivotto I, Parpia S, Berrang T, Kim D, Kong I, Truong P, Cochrane B, Julian J, RAPID Trial Investigators Interim toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation (APBI) using 3D conformal external beam radiation therapy (3D CRT) [Abstract]. Presented at the American Society for Radiation Oncology 54th Annual Meeting, October 28–31, 2012, Boston, MA. Int J Radiat Oncol Phys. 2013;85:21–22.
    1. Leonard KL, Hepel JT, Hiatt JR, Dipetrillo TA, Price LL, Wazer DE. The effect of dose-volume parameters and interfraction interval on cosmetic outcome and toxicity after 3-dimensional conformal accelerated partial breast irradiation. Int J Radiat Oncol Phys. 2013;85:623–629. doi: 10.1016/j.ijrobp.2012.06.052.
    1. Lewin AA, Derhagopian R, Saigal K, Panoff JE, Abitbol A, Wieczorek DJ, Mishra V, Reis I, Ferrell A, Moreno L, Takita C. Accelerated partial breast irradiation is safe and effective using intensity-modulated radiation therapy in selected early-stage breast cancer. Int J Radiat Oncol Phys. 2012;82:2104–2110. doi: 10.1016/j.ijrobp.2011.02.024.
    1. Jagsi R, Ben-David MA, Moran JM, Marsh RB, Griffith KA, Hayman JA, Pierce LJ. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:71–78. doi: 10.1016/j.ijrobp.2009.01.041.
    1. Livi L, Buonamici FB, Simontacchi G, Scotti V, Fambrini M, Compagnucci A, Paiar F, Scoccianti S, Pallotta S, Detti B, Agresti B, Talamonti C, Mangoni M, Bianchi S, Cataliotti L, Marrazo L, Bucciolini M, Biti G. Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2010;77:509–515. doi: 10.1016/j.ijrobp.2009.04.070.
    1. Leonard CE, Carter DL, Kercher J, et al. Prospective trial of accelerated partial breast intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1291–1298. doi: 10.1016/j.ijrobp.2006.11.016.
    1. Leonard CE, Tallhamer M, Johnson T, Hunter K, Howell K, Kercher J, Widener J, Kaske T, Paul D, Sedlacek S, Carter Clinical experience with image-guided radiotherapy in an accelerated partial breast intensity-modulated radiotherapy protocol. Int J Radiat Oncol Biol Phys. 2010;76:234–528.
    1. Rusthoven KE, Carter DL, Howell K, Kercher JM, Henkenberns P, Hunter KL, Leonard CE. Accelerated partial-breast intensity-modulated radiotherapy results in improved dose distribution when compared with three-dimensional treatment-planning techniques. Int J Radiat Oncol Biol Phys. 2008;70:296–302. doi: 10.1016/j.ijrobp.2007.08.047.
    1. Reeder R, Carter DL, Howell K, Henkenberns P, Tallhamer M, Johnson T, Kercher J, Widner J, Kaske T, Paul D, Sedlacek S, Leonard CE. Predictors for clinical outcomes after accelerated partial breast intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2009;74:92–97. doi: 10.1016/j.ijrobp.2008.06.1917.
    1. Kozak KR, Smith BL, Adams J, Kornmehl E, Katz A, Gadd M, Specht M, Hughes K, Gioioso V, Lu HM, Braaten K, Recht A, Powell SN, DeLaney TF, Taghian AG. Accelerated partial-breast irradiation using proton beams: initial clinical experience. Int J Radiat Oncol Biol Phys. 2006;66:691–698. doi: 10.1016/j.ijrobp.2006.06.041.
    1. Wang X, Amos RA, Zhang X, Taddei PJ, Woodward WA, Hoffman KE, Yu TK, Tereffe W, Oh J, Perkins GH, Salehpour M, Zhang SX, Sun TL, Gillin M, Buchholz TA, Strom EA. External-beam accelerated partial breast irradiation using multiple proton beam configurations. Int J Radiat Oncol Biol Phys. 2011;80:1464–1472. doi: 10.1016/j.ijrobp.2010.04.052.
    1. Leonardi MC, Ivaldi GB, Santoro L, Lazzari R, Ferrari A, Morra A, Caldarella P, Burgoa L, Bassi FD, Sangalli C, Rotmensz N, Luini A, Veronesi U, Orecchia R. Long-term side effects and cosmetic outcome in a pool of breast cancer patients treated with intraoperative radiotherapy with electrons as sole treatment. Tumori. 2012;98:324–330.
    1. Vaidya JS, Wenz F, Bulsara M, Joseph D, Tobias JS, Keshtgar M, Flyger H, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sutterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg H, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A Trial-updated analysis of local recurrence and first analysis of survival [Abstract]. Presented at the 35th annual San Antonio breast cancer symposium, December 4–8, San Antonio, TX. Cancer Research. 2012;72(Suppl):100s–101s.
    1. Beal K, Sacchini V, Zelefsky M, Rogers KH, McCormick B. Five year update on intraoperative radiation therapy for breast cancer [Abstract]. Presented at the American Society for Radiation Oncology 53rd Annual Meeting, October 2–6, Miami Beach, FL. Int J Radiat Oncol Phys. 2012;81(Suppl):S241–S242.
    1. Vanderwalde NA, Jones EL, Kimple RJ, Moore DT, Klauber-Demore N, Sartor CI, Ollila DW. Phase 2 study of pre-excision single-dose intraoperative radiation therapy for early-stage breast cancers: six-year update with application of the ASTRO accelerated partial breast irradiation consensus statement criteria. Cancer. 2013;119:1736–1743. doi: 10.1002/cncr.27915.
    1. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, Julian TB, Marks LB, Todor DA, Vicini FA, Whelan TJ, White J, Wo JY, Harris JR. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) Int J Radiat Oncol Biol Phys. 2009;74:987–1001. doi: 10.1016/j.ijrobp.2009.02.031.
    1. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–1129. doi: 10.1016/j.ijrobp.2007.11.044.
    1. Sharma NK, Li T, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80:437–444. doi: 10.1016/j.ijrobp.2010.02.040.
    1. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stürmer T, Holmes JA, Reeve BB, Godley PA, Carpenter WR, Chen RC. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611–1620. doi: 10.1001/jama.2012.460.
    1. Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, Vu TT, Truong P, Ackerman I, Paszat L. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26:2085–2092. doi: 10.1200/JCO.2007.15.2488.
    1. Barnett GC, Wilkinson J, Moody AM, Wilson CB, Sharma R, Klager S, Hoole AC, Twyman N, Burnet NG, Coles CE. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. Radiother Oncol. 2009;92:34–41. doi: 10.1016/j.radonc.2009.03.003.
    1. Hardee ME, Raza S, Becker SJ, Jozsef G, Lymberis SC, Hochman T, Goldberg JD, DeWyngaert KJ, Formenti SC. Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. Int J Radiat Oncol Biol Phys. 2012;82:e415–e423. doi: 10.1016/j.ijrobp.2011.06.1950.
    1. Freedman GM, Li T, Nicolaou N, Chen Y, Ma CC, Anderson PR. Breast intensity-modulated radiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation. Int J Radiat Oncol Biol Phys. 2009;74:689–694. doi: 10.1016/j.ijrobp.2008.08.071.
    1. McDonald MW, Godette KD, Butker EK, Davis LW, Johnstone PA. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis. Int J Radiat Oncol Biol Phys. 2008;72:1031–1040. doi: 10.1016/j.ijrobp.2008.02.053.
    1. Harsolia A, Kestin L, Grills I, Wallace M, Jolly S, Jones C, Lala M, Martinez A, Schell S, Vicini FA. Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1375–1380. doi: 10.1016/j.ijrobp.2007.02.044.
    1. Recht A, Silver B, Schnitt S, Connolly J, Hellman S, Harris JR. Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. Int J Radiat Oncol Biol Phys. 1985;11:1271–1276. doi: 10.1016/0360-3016(85)90241-X.
    1. Kühr M, Wolfgarten M, Stölzle M, Leutner C, Holler T, Schrading S, Kuhn W, Braun M. Potential impact of preoperative magnetic resonance imaging of the breast on patient selection for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2011;81:e541–e546. doi: 10.1016/j.ijrobp.2011.04.035.
    1. Dorn PL, Al-Hallaq HA, Haq F, Goldberg M, Abe H, Hasan Y, Chmura SL. A prospective study of the utility of magnetic resonance imaging in determining candidacy for partial breast irradiation. Int J Radiat Oncol Biol Phys. 2013;85:615–622. doi: 10.1016/j.ijrobp.2012.06.014.
    1. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R, Early Breast Cancer Trialists’ Collaborative Group Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–1716. doi: 10.1016/S0140-6736(11)61629-2.
    1. Mannino M, Yarnold JR. Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld? Radiother Oncol. 2009;90:14–22. doi: 10.1016/j.radonc.2008.05.002.
    1. Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, Hildebrandt G, Niehoff P, Guinot JL, Guedea F, Johansson B, Ott OJ, Major T, Strnad V, GEC-ESTRO breast cancer working group Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009) Radiother Oncol. 2010;94:264–273. doi: 10.1016/j.radonc.2010.01.014.
    1. Board of Directors ASoBS (2011) Consenus statement for accelerated partial breast irradiation. . Accessed 14 June 2013
    1. Breast Brachytherapy Task Group, ABS (2007) ABS Breast Brachytherapy Task Group. . Accessed 14 June 2013
    1. Vicini F, Arthur D, Wazer D, Chen P, Mitchell C, Wallace M, Kestin L, Ye H. Limitations of the American Society of Therapeutic Radiology and Oncology Consensus Panel guidelines on the use of accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2011;79:977–984. doi: 10.1016/j.ijrobp.2009.12.047.
    1. Shaitelman SF, Vicini FA, Beitsch P, Haffty B, Keisch M, Lyden M. Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer. 2010;116:4677–4685. doi: 10.1002/cncr.25383.
    1. Amin N, Konski AA (2013) Is hypofractionation the solution? The financial implications of breast cancer treatments. Oncology vol 27. April 15, 2013. . Accessed 12 June 2013
    1. Dwyer P, Hickey B, Burmeister E, Burmeister B. Hypofractionated whole-breast radiotherapy: impact on departmental waiting times and cost. J Med Imaging Radiat Oncol. 2010;54:229–234. doi: 10.1111/j.1754-9485.2010.02163.x.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe